Medical devices, healthcare technology and the business of care
510(k) clearance · K262390

BoneXpert

Visiana · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONK262390

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for BoneXpert, a Visiana premarket notification assigned K262390, with a decision date of September 22, 2026 and receipt date of July 13, 2026. The device is classified under 21 CFR 892.2050 as a medical image management and processing system, Class II, product code QIH, in the radiology specialty. SESE denotes 510(k) clearance, not premarket approval.

The submission describes DICOM software that estimates bone age from posterior-anterior pediatric hand radiographs using machine learning and the Greulich-Pyle method, returning an annotated image for radiologist review. The stated predicate is EFAI Bonesuite XR Bone Age Pro Assessment System (K234042); the summary notes differences in algorithm type and accepted hand laterality. The summary cites a Stanford multicenter study of 1,285 images from five U.S. sites, but the provided excerpts give no performance results, and the full indications enclosure is only partially legible.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Sep 22, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262390
Regulatory pathway
510(k) premarket notification
Applicant
Visiana
Product code
QIH
Decision code
SESE
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated Radiological Image Processing Software.

Applicant
Visiana
Product code
QIH
FDA device class
2

FDA decision timeline

  1. K262390 received

    Application receipt date recorded by FDA.

  2. K262390 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QIH

Product / regulatory recordCompanyPathwayDecision dateSource
Clever OneK260372
Ewoosoft Co., Ltd.510(k) clearanceNov 4, 2026FDA
Peek Health, S.A.510(k) clearanceNov 4, 2026FDA
AVICENNA.AI510(k) clearanceOct 19, 2026FDA
UAB Ligence510(k) clearanceOct 7, 2026FDA
NeuroDRK262134
Deep Reasoning Ai, Inc.510(k) clearanceOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Visiana

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Horsholm

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records